4Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long term follow-up. Am J Surg Pathol, 2005, 29: 52-68. 被引量：1
5De Giorgi U, Verweij J. Imatinib and gastrointestinal stromal tumors:Where do we go from here? Mol Cancer Ther, 2005, 4: 495-501. 被引量：1
6Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistoehemical, andmolecular genetic study of 906 cases before imatinib with long term follow up. Am J Surg Pathol, 2006, 30: 477-489. 被引量：1
7Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol, 2003, 21: 4249-4342. 被引量：1
8Lasota J, Corless CL, Heinrich MC, et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol, 2008, 21 : 476-484. 被引量：1
9Corless CL, SchroederA, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol, 2005, 23: 5357-5364. 被引量：1
10Dirnhofer S, Zimpfer A,Went P. The diagnostic and predictive role of kit(CD117). Ther Umsch, 2006, 63:273-278. 被引量：1
8Giovannini M, Seitz JF, Monges G, et al. Fine-needle aspiration cytology guided by endoscopic ultrasonography : results in 141 patients. Endoscopy, 1995, 27: 171-177. 被引量：1
9Varadarajulu S, Fraig M, Schmulewitz N, et al. Comparison of EUS-guided 19-gauge Trucut needle biopsy with EUS-guided fine-needle aspiration. Endoscopy, 2004, 36: 397-401. 被引量：1
10Park YS, Park SW, Kim TI, et al. Endoscopic enucleation of upper-G1 submucosal tumors by using an insulated-tip electrosurgical knife. Gastrointest Endosc, 2004, 59: 409-415. 被引量：1
2Wynn ML, Ventura AC, Sepulchre JA, et al. Kinase inhibitors canproduce off-target effects and activate linked pathways by retroactivity. BMC Syst Biol, 2011,5(1) :156. 被引量：1
3Han W, Pan H, Chen Y, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One, 2011,6(6) :e18691. 被引量：1
5Scahriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst, 2007, 99 (8) :628-638. 被引量：1
6Zhang J, Roberts TM, Shivdasani RA. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology, 2011, 141 ( 1 ) :50-61. 被引量：1
7Tzvetkov MV, Behrens G, O'Brien VP, et al. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics, 2011, 12(10) : 1417-1427. 被引量：1
8Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer, 2009, 9(5) :338-350. 被引量：1
9Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One, 2008, 3 ( 11 ) : e3695. 被引量：1
10Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol, 2008, 26(13) :2131-2138. 被引量：1
